Lucida Medical’s AI software for prostate cancer diagnosis added to TeraRecon’s platform
Lucida Medical’s AI-based software to aid prostate cancer diagnosis has been added to TeraRecon’s platform for use within the NHS and European healthcare systems.
It represents an important deal for the Cambridge company, as it provides easy access for hospitals to adopt its PI (Prostate Intelligence) software, which helps radiologists to detect prostate cancer lesions from MRI scans.
TeraRecon, a ConcertAI company, will add the software to its Eureka Clinical AI platform, which provides first, second and third party algorithms and features a console enabling medics to see all results and conversations across a patient’s healthcare teams.
Dr Antony Rix, CEO and co-founder of Lucida Medical, said: “We are delighted to empower the wide community of TeraRecon users with our MR-based prostate solution. This global partnership brings healthcare providers closer to achieving faster and more accurate detection of the most common cancer in men.”
MRI is the preferred technique to assess a number of cancers, including prostate and metastatic disease but interpreting the scans requires specialist training and is labour-intensive, which has led to a growing skills shortage.
The PROMIS study found radiologists can miss 12 per cent of significant cancers on MRI, while 55 per cent of individuals without significant cancer end up with a painful and costly biopsy.
Studies show Lucida Medical’s machine learning technology, which recently earned a CE mark, could help cut missed cancers to 7 per cent and unnecessary biopsies to 24 per cent, while helping speed up the process.
Dan McSweeney, president of North Carolina-based TeraRecon, said: “The addition of Lucida Medical’s PI solution enhances TeraRecon's comprehensive AI offerings, particularly in prostate and oncology patient care. By integrating Prostate Intelligence, we hope to significantly improve the prostate cancer diagnostic pathway with technology that helps radiologists find cancer by analysing MRI, enabling radiologists to have a tool to support their role in identification of a disease state and patients to receive the most appropriate care for their condition.”
